Annexon Biosciences

Annexon Biosciences Overview

Founded 2011
Founded
Status Private
Latest Deal Type Series C
Latest Deal Amount $75M
Latest Deal Amount
Investors 12

Annexon Biosciences General Information

Description

Developer of novel therapeutics intended to treat neurodegenerative disorders. The company's therapeutics includes a pipeline of classical complement pathway inhibitors focused on therapies for complement-mediated loss of nerve connections in the brain as well as in retinal cells for the diseases like Alzheimer's disease Huntington's disease and glaucoma, enabling medical practitioners to protect patients from synapse loss and inflammatory nerve damage in brain and retinal cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 180 Kimball Way
  • 2nd Floor, Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Annexon Biosciences Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Annexon Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 19-Dec-2018 $75M 00000 00000 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series B) 23-Jun-2016 0000 0000 000.00 Completed Clinical Trials - Phase 1
4. Accelerator/Incubator 01-Jan-2015 0000 Completed Startup
3. Early Stage VC (Series A1) 15-Dec-2014 0000 0000 000.00 Completed Startup
2. Early Stage VC (Series A) $1000K $1000K 0000 Completed Startup
1. Seed Round 01-Jan-2011 Completed Startup

Annexon Biosciences Cap Table

To view Annexon Biosciences‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 16,398,995 $0.001000 $0.06 $1.05 $1.05 1x $1.05 11.65%
Series A 1,015,434 $0.001000 $0.98 $0.98 1x $0.98 0.72%

Annexon Biosciences Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Cadent Therapeutics Venture Capital-Backed Cambridge, MA 0 000.00 00000000000 000.00
000000 00000000000 Venture Capital-Backed South San Francisco, CA 00 00000 000000000000 00000
0000000 0000000000 Venture Capital-Backed Baltimore, MD 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 0000 00.000
000000000 00000000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 000.00

Annexon Biosciences Executive Team (9)

Name Title Board Seat Contact Info
Douglas Love JD Chief Executive Officer, President & Board Member
Jennifer Lew Chief Financial Officer
Ted Yednock Ph.D Chief Scientific Officer & Executive Vice President
Lesley Stolz Ph.D Chief Business Officer
Sanjay Keswani Chief Medical Officer

4 Former Executives

Annexon Biosciences Board Members (12)

To view Annexon Biosciences‘s full board member team, request access »
Name Representing Role Since
Campbell Murray MD Novartis Venture Fund Board Member 000 0000
Carol Gallagher New Enterprise Associates Board Member 000 0000
Douglas Love JD Annexon Biosciences Chief Executive Officer, President & Board Member 000 0000
Emmett Cunningham Ph.D Blackstone Life Sciences Board Member 000 0000
Frank Torti MD New Enterprise Associates Board Member 000 0000

1 Former Board Member

Annexon Biosciences Investors (12)

To view Annexon Biosciences‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adage Capital Management Hedge Fund Minority 000 0000 000000 0
Bain Capital PE/Buyout Minority 000 0000 000000 0
Citadel (Hedge Fund) Hedge Fund Minority 000 0000 000000 0
Satter Investment Management Other Minority 000 0000 000000 0
The Blackstone Group PE/Buyout Minority 000 0000 000000 0

Ready to get started?

Request a free trial